SrasV1, Main, Exploration, bibRecord, 005B19

Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV

Identifieur interne : 005B19 ( Main/Exploration ); précédent : 005B18; suivant : 005B20

Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV

Auteurs : Miriam E. R. Darnell [États-Unis] ; Kanta Subbarao [États-Unis] ; Stephen M. Feinstone [États-Unis] ; Deborah R. Taylor [États-Unis]

Source :

Journal of virological methods [ 0166-0934 ] ; 2004.

RBID : Pascal:04-0535983

Descripteurs français

KwdFr :
- Animaux, Antiviraux (pharmacologie), Cellules Vero, Cinétique, Concentration en ions d'hydrogène, Facteurs temps, Formaldéhyde (pharmacologie), Glutaraldéhyde (pharmacologie), Inactivation virale, Rayons ultraviolets, Température élevée, Virus du SRAS (), Virus du SRAS (effets des radiations), Virus du SRAS (physiologie).
MESH :
- effets des radiations : Virus du SRAS.
- pharmacologie : Antiviraux, Formaldéhyde, Glutaraldéhyde.
- physiologie : Virus du SRAS.
Pascal (Inist)
- Animaux, Cellules Vero, Cinétique, Concentration en ions d'hydrogène, Coronavirus, Culture tissu, Facteurs temps, Inactivation virale, Microbiologie, Méthode, Rayons ultraviolets, Température élevée, Virologie, Syndrome respiratoire aigu sévère, Virus du SRAS.

English descriptors

KwdEn :
- Animals, Antiviral Agents (pharmacology), Chlorocebus aethiops, Coronavirus, Formaldehyde (pharmacology), Glutaral (pharmacology), Hot Temperature, Hydrogen-Ion Concentration, Kinetics, Method, Microbiology, SARS Virus (drug effects), SARS Virus (physiology), SARS Virus (radiation effects), Severe acute respiratory syndrome, Time Factors, Tissue culture, Ultraviolet Rays, Vero Cells, Virology, Virus Inactivation.
MESH :
- chemical , pharmacology : Antiviral Agents, Formaldehyde, Glutaral.
- drug effects : SARS Virus.
- physiology : SARS Virus.
- radiation effects : SARS Virus.
- Animals, Chlorocebus aethiops, Hot Temperature, Hydrogen-Ion Concentration, Kinetics, Time Factors, Ultraviolet Rays, Vero Cells, Virus Inactivation.

Abstract

Severe acute respiratory syndrome (SARS) is a life-threatening disease caused by a novel coronavirus termed SARS-CoV. Due to the severity of this disease, the World Health Organization (WHO) recommends that manipulation of active viral cultures of SARS-CoV be performed in containment laboratories at biosafety level 3 (BSL3). The virus was inactivated by ultraviolet light (UV) at 254 nm, heat treatment of 65 °C or greater, alkaline (pH > 12) or acidic (pH < 3) conditions, formalin and glutaraldehyde treatments. We describe the kinetics of these efficient viral inactivation methods, which will allow research with SARS-CoV containing materials, that are rendered non-infectious, to be conducted at reduced safety levels.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112912

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV</title>
<author><name sortKey="Darnell, Miriam E R" sort="Darnell, Miriam E R" uniqKey="Darnell M" first="Miriam E. R." last="Darnell">Miriam E. R. Darnell</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Feinstone, Stephen M" sort="Feinstone, Stephen M" uniqKey="Feinstone S" first="Stephen M." last="Feinstone">Stephen M. Feinstone</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Taylor, Deborah R" sort="Taylor, Deborah R" uniqKey="Taylor D" first="Deborah R." last="Taylor">Deborah R. Taylor</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0535983</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0535983 INIST</idno>
<idno type="RBID">Pascal:04-0535983</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000794</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000196</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000829</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000829</idno>
<idno type="wicri:doubleKey">0166-0934:2004:Darnell M:inactivation:of:the</idno>
<idno type="wicri:Area/Main/Merge">005F80</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112912</idno>
<idno type="RBID">PMC:7112912</idno>
<idno type="wicri:Area/Pmc/Corpus">001227</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001227</idno>
<idno type="wicri:Area/Pmc/Curation">001227</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001227</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001628</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001628</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15350737</idno>
<idno type="wicri:Area/PubMed/Corpus">002B77</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002B77</idno>
<idno type="wicri:Area/PubMed/Curation">002B77</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002B77</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002C41</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C41</idno>
<idno type="wicri:Area/Ncbi/Merge">000A49</idno>
<idno type="wicri:Area/Ncbi/Curation">000A49</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000A49</idno>
<idno type="wicri:doubleKey">0166-0934:2004:Darnell M:inactivation:of:the</idno>
<idno type="wicri:Area/Main/Merge">005695</idno>
<idno type="wicri:Area/Main/Curation">005B19</idno>
<idno type="wicri:Area/Main/Exploration">005B19</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV</title>
<author><name sortKey="Darnell, Miriam E R" sort="Darnell, Miriam E R" uniqKey="Darnell M" first="Miriam E. R." last="Darnell">Miriam E. R. Darnell</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Feinstone, Stephen M" sort="Feinstone, Stephen M" uniqKey="Feinstone S" first="Stephen M." last="Feinstone">Stephen M. Feinstone</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Taylor, Deborah R" sort="Taylor, Deborah R" uniqKey="Taylor D" first="Deborah R." last="Taylor">Deborah R. Taylor</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of virological methods</title>
<title level="j" type="abbreviated">J. virol. methods</title>
<idno type="ISSN">0166-0934</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of virological methods</title>
<title level="j" type="abbreviated">J. virol. methods</title>
<idno type="ISSN">0166-0934</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Chlorocebus aethiops</term>
<term>Coronavirus</term>
<term>Formaldehyde (pharmacology)</term>
<term>Glutaral (pharmacology)</term>
<term>Hot Temperature</term>
<term>Hydrogen-Ion Concentration</term>
<term>Kinetics</term>
<term>Method</term>
<term>Microbiology</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>SARS Virus (radiation effects)</term>
<term>Severe acute respiratory syndrome</term>
<term>Time Factors</term>
<term>Tissue culture</term>
<term>Ultraviolet Rays</term>
<term>Vero Cells</term>
<term>Virology</term>
<term>Virus Inactivation</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Cellules Vero</term>
<term>Cinétique</term>
<term>Concentration en ions d'hydrogène</term>
<term>Facteurs temps</term>
<term>Formaldéhyde (pharmacologie)</term>
<term>Glutaraldéhyde (pharmacologie)</term>
<term>Inactivation virale</term>
<term>Rayons ultraviolets</term>
<term>Température élevée</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (effets des radiations)</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Formaldehyde</term>
<term>Glutaral</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des radiations" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Formaldéhyde</term>
<term>Glutaraldéhyde</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="radiation effects" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Hot Temperature</term>
<term>Hydrogen-Ion Concentration</term>
<term>Kinetics</term>
<term>Time Factors</term>
<term>Ultraviolet Rays</term>
<term>Vero Cells</term>
<term>Virus Inactivation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term>
<term>Cellules Vero</term>
<term>Cinétique</term>
<term>Concentration en ions d'hydrogène</term>
<term>Coronavirus</term>
<term>Culture tissu</term>
<term>Facteurs temps</term>
<term>Inactivation virale</term>
<term>Microbiologie</term>
<term>Méthode</term>
<term>Rayons ultraviolets</term>
<term>Température élevée</term>
<term>Virologie</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a life-threatening disease caused by a novel coronavirus termed SARS-CoV. Due to the severity of this disease, the World Health Organization (WHO) recommends that manipulation of active viral cultures of SARS-CoV be performed in containment laboratories at biosafety level 3 (BSL3). The virus was inactivated by ultraviolet light (UV) at 254 nm, heat treatment of 65 °C or greater, alkaline (pH > 12) or acidic (pH < 3) conditions, formalin and glutaraldehyde treatments. We describe the kinetics of these efficient viral inactivation methods, which will allow research with SARS-CoV containing materials, that are rendered non-infectious, to be conducted at reduced safety levels.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Darnell, Miriam E R" sort="Darnell, Miriam E R" uniqKey="Darnell M" first="Miriam E. R." last="Darnell">Miriam E. R. Darnell</name>
</region>
<name sortKey="Feinstone, Stephen M" sort="Feinstone, Stephen M" uniqKey="Feinstone S" first="Stephen M." last="Feinstone">Stephen M. Feinstone</name>
<name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<name sortKey="Taylor, Deborah R" sort="Taylor, Deborah R" uniqKey="Taylor D" first="Deborah R." last="Taylor">Deborah R. Taylor</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005B19 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005B19 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:04-0535983
   |texte=   Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV

Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.